The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional ...

North Dakota lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

This page features the latest news about the Novo Nordisk B stock. Novo Nordisk Q3 sales ... 4,130 (+3.5%); Diabetes and Obesity Care: 1,480 (+9.4%); Biopharmaceuticals: 383 (-11.1%).Modern ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Health-care companies rose as traders rotated into defensive areas ahead of key jobs data.

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...